News | February 05, 2026
AbbVie posts higher revenue in 2025, led by immunology & neuroscience growth
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
This recognition demonstrate excellence in intellectual property (IP) value creation.
The company had achieved the highest "A" rating in Climate Change
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Subscribe To Our Newsletter & Stay Updated
